Aftab Blake 4

What Happened

• Aftab Blake, Chief Scientific Officer of Adicet Bio, was granted 55,000 shares on 2026-06-19. The award is reported as a derivative acquisition at $0.00 per share (Form 4 code A). The grant vests 1/48th each month for 48 months and includes partial acceleration tied to certain performance milestones, subject to continued service.

Key Details

• Transaction date: 2026-06-19; Form 4 filed 2026-06-23 (timely).
• Instrument/Transaction type: Grant/Award (derivative), acquisition price reported $0.00.
• Shares granted: 55,000.
• Vesting: 1/48th monthly over 48 months; partial acceleration possible upon specified performance milestones, provided the reporting person remains in service.
• Shares owned after transaction: Not specified in the provided data.
• Filing accession: 0001886986-26-000004.

Context

• This was a compensation grant (not a market purchase or sale). Such awards are common for executives and are intended to align incentives; they do not represent an immediate cash investment or sale. The partial acceleration clause ties some vesting to performance metrics, which can affect future dilution and executive incentives.